Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis
about
Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal managementProfile of oritavancin and its potential in the treatment of acute bacterial skin structure infectionsManagement of multidrug-resistant enterococcal infectionsTreatment and prevention of infective endocarditis.Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infectionOritavancin diphosphateOritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria.Oritavancin for acute bacterial skin and skin structure infections.Oritavancin: a new avenue for resistant Gram-positive bacteria.Oritavancin--an investigational glycopeptide antibiotic.Antimicrobial therapy of Staphylococcus aureus bloodstream infection.Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.Emergence and management of drug-resistant enterococcal infections.A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.Oritavancin: A Long-Half-Life Lipoglycopeptide.Enterococcal endocarditis revisited.Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci.Oritavancin: a long-acting antibacterial lipoglycopeptide.Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-resistant Enterococcus faecium Isolates in an In Vitro PK/PD Model of Infection.Oritavancin Pharmacokinetics and Bone Penetration in Rabbits.The in vitro contribution of autolysins to bacterial killing elicited by amoxicillin increases with inoculum size in Enterococcus faecalisMeningitis due to vancomycin-resistant Enterococcus faecium successfully treated with combined intravenous and intraventricular chloramphenicol.Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus.In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans.
P2860
Q26798630-5E0D82D2-EDC0-4935-8B50-40AA56FDCE3FQ26799701-038616F7-F73F-4712-ABE7-69C3DC8CFD91Q28285907-5001CF3C-73C5-45B1-8AD4-CD05974BB47FQ34519242-B02E8D6E-D4C0-4138-A640-9559A104C186Q34937444-CB25E61C-55F1-4D55-A2D6-79C9A01A2A31Q35057973-A7872FC2-6F44-43FB-9145-1BE786C394B3Q35637071-2C45104A-8149-4D01-B3FE-FB2EB426D781Q36086423-2C5CBA55-8244-4031-ACAA-D3A83EB92163Q36162339-14BC2029-F0B0-4AB5-930A-A32A8134F8EEQ36426011-0FE95C77-B43E-43EF-A4AA-A1BDBC113FE9Q36968150-75FACE3E-C3F4-4064-8B7A-D5A927789D3FQ37071199-14734355-BEEF-4361-8796-37D90F92D512Q37174100-803E4EA0-1616-424B-8710-73CC8FF6307AQ37291346-B9E87617-A1DB-45C6-8919-A1923031EE2EQ37661510-C2091A1A-D964-49AB-9576-47C56B278E93Q38434265-617ABC98-D589-455F-A5CF-22256DDF605AQ38539279-9EC48C48-4936-4463-8AED-B32D5679D3D4Q38577676-94CDBCCF-6392-4F7E-9CD3-FC9BAE7A5DC1Q38830176-B9F4E659-8839-4DC0-B164-E9F71C4A41F5Q40103272-B924B61F-82FB-490B-BD7F-58688C2F6E99Q41073732-B7CFB206-2624-4F99-87DD-0EAF960D501CQ42583033-4F1A32A6-2503-4F95-9538-D8771AA8C3E8Q42593900-4554FE76-F236-45F5-A3AF-939CC8CFE2FAQ43169904-5F9E6D7C-599D-4A5F-98F5-59AB757E9617Q43189837-DCE86EB5-5CF9-41DB-8A4C-4CC549F4EECBQ51760113-A914B26B-6E92-42DA-9797-696AAD072C05
P2860
Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Activity of LY333328 combined ...... esistant Enterococcus faecalis
@ast
Activity of LY333328 combined ...... esistant Enterococcus faecalis
@en
type
label
Activity of LY333328 combined ...... esistant Enterococcus faecalis
@ast
Activity of LY333328 combined ...... esistant Enterococcus faecalis
@en
prefLabel
Activity of LY333328 combined ...... esistant Enterococcus faecalis
@ast
Activity of LY333328 combined ...... esistant Enterococcus faecalis
@en
P2093
P2860
P1476
Activity of LY333328 combined ...... esistant Enterococcus faecalis
@en
P2093
P2860
P304
P356
10.1128/AAC.44.11.3017-3021.2000
P407
P577
2000-11-01T00:00:00Z